DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM) has been assigned a consensus rating of “Moderate Buy” from the twenty-seven ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, twenty-one have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $84.88.

Several research analysts have recently weighed in on DXCM shares. Raymond James Financial reissued a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a research report on Monday, June 8th. Robert W. Baird set a $80.00 target price on DexCom in a research note on Friday, May 1st. Canaccord Genuity Group set a $82.00 target price on DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Citigroup reiterated a “buy” rating and issued a $84.00 target price (up from $79.00) on shares of DexCom in a report on Thursday, May 28th. Finally, Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target on the stock in a research note on Tuesday, March 24th.

DexCom Trading Up 2.7%

Shares of DXCM traded up $1.94 during trading hours on Friday, hitting $74.96. 3,856,779 shares of the stock were exchanged, compared to its average volume of 4,451,275. DexCom has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The business has a 50-day moving average of $69.62 and a 200-day moving average of $68.44. The firm has a market capitalization of $28.92 billion, a P/E ratio of 32.03, a price-to-earnings-growth ratio of 1.23 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.32 earnings per share. On average, research analysts expect that DexCom will post 2.57 EPS for the current year.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares in the company, valued at $3,917,918.76. The trade was a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,450 shares of company stock worth $5,270,409 over the last ninety days. 0.28% of the stock is owned by company insiders.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently made changes to their positions in DXCM. Gradient Investments LLC lifted its position in shares of DexCom by 13.8% during the 4th quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock valued at $22,035,000 after buying an additional 40,343 shares during the last quarter. Nordea Investment Management AB increased its holdings in DexCom by 118.6% in the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock worth $16,988,000 after acquiring an additional 137,986 shares during the last quarter. Banque Pictet & Cie SA increased its holdings in DexCom by 58.2% in the 4th quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock worth $7,289,000 after acquiring an additional 40,411 shares during the last quarter. Holocene Advisors LP bought a new stake in DexCom in the 3rd quarter valued at about $163,964,000. Finally, Aberdeen Group plc raised its stake in DexCom by 9.0% in the 4th quarter. Aberdeen Group plc now owns 530,363 shares of the medical device company’s stock valued at $35,200,000 after acquiring an additional 43,990 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.